EKF Molecular Diagnostics has agreed a collaboration with specialist medtech company ANGLE plc, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan™ DNA enrichment...
Your new post is loading...
Your new post is loading...
|
Xianglei WU's comment,
June 7, 2014 4:46 PM
seems to weaken the comparability of CTC quantification results from different patients ?
|